Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?

BMC Cancer

Alberto Farolfi⁶  Elisa Carretta³  Corradina Della Luna⁵  Angela Ragazzini³  Nicola Gentili⁴  Carla Casadei²  Domenico Barone¹  Martina Minguzzi³  Dino Amadori⁶  Oriana Nanni³  Giampaolo Gavelli¹ 

[1] Radiology Unit, IRST IRCCS, via Piero Maroncelli 40, Meldola 47014, Italy

[2] Anesthesiology Unit, IRST IRCCS, via Piero Maroncelli 40, Meldola 47014, Italy

[3] Unit of Biostatistics and Clinical Trials, IRST IRCCS, via Piero Maroncelli 40, Meldola 47014, Italy

[4] IT Unit, IRST IRCCS, via Piero Maroncelli 40, Meldola 47014, Italy

[5] Oncology Pharmacy, IRST IRCCS, via Piero Maroncelli 40, Meldola 47014, Italy

[6] Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Piero Maroncelli 40, Meldola 47014, Italy

关键词: Cancer patients and chemotherapy;    Contrast-enhanced CT;    Hypersensitivity;    Time to adverse reaction;    Iodinated contrast media;   

Others  :  1120946
DOI  :  10.1186/1471-2407-14-792

 received in 2014-07-02, accepted in 2014-10-17,  发布年份 2014

【 摘 要 】

Background

Cancer patients undergo routine computed-tomography (CT) scans and, therefore, iodinated contrast media (ICM) administration. It is not known whether a time-dependent correlation exists between chemotherapy administration, contrast enhanced CT and onset of acute ICM-related adverse reactions (ARs).

Methods

All consecutive contrast-enhanced CTs performed from 1 January 2010 to 31 December 2012 within 30 days of the last chemotherapy administration were retrospectively reviewed. Episodes of acute ICM-related ARs were reported to the pharmacovigilance officer. We analyzed time to CT evaluation calculated as the time elapsed from the date of the CT performed to the date of the last chemotherapy administration. Patients were classified into 4 groups based on the antineoplastic treatment: platinum-based, taxane-based, platinum plus taxane and other group.

Results

Out of 10,472 contrast-enhanced CTs performed, 3,945 carried out on 1,878 patients were considered for the study. Forty acute ICM-related ARs (1.01%; 95% CI, 0.70-1.33) were reported. No differences were seen among immediate (within 10 days of the last chemotherapy administration), early (11–20 days) and delayed (21–30 days) CTs. Median time to CT in patients who experienced an acute ICM-related AR by treatment group was not statistically different: 20 days (range 6–30), 17 days (range 5–22), 13 days (range 8–17), 13 days (range (2–29) for the platinum, taxane, platinum plus taxane and other group, respectively (P =0.251).

Conclusions

Our results did not reveal any correlation between time to CT and risk of acute ICM-related ARs in cancer patients.

【 授权许可】

   
2014 Farolfi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R, EUROCARE-5 Working Group: Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014, 5:23-34.
• [2]Farolfi A, Della Luna C, Ragazzini A, Carretta E, Gentili N, Casadei C, Aquilina M, Barone D, Minguzzi M, Amadori D, Nanni O, Gavelli G: Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients. Oncologist 2014, 19:823-828.
• [3]Katayama H: Adverse reactions to contrast media: what are the risk factors? Invest Radiol 1990, 25(Suppl 1):S16-S17. no abstract available
• [4]Cochran ST, Bomyea K, Sayre J: Trends in adverse events from iodinated contrast media. Acad Radiol 2002, 9(Suppl 1):S65-S68. no abstract available
• [5]Mortelé KJ, Oliva MR, Ondategui S, Ros PR, Silverman SG: Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital. AJR 2005, 185:31-34.
• [6]Wang CL, Cohan RH, Ellis JH, Caoili EM, Wang G, Francis IR: Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol 2008, 191:409-415.
• [7]Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y: Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2011, 8:332-338.
• [8]Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y: Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res 2011, 30:93. BioMed Central Full Text
• [9]Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 1990, 8:1263-1268.
• [10]Bush WH, Swanson DP: Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR 1991, 157:1153-1161.
• [11]Brockow K: Contrast media hypersensitivity–scope of the problem. Toxicology 2005, 209:189-192.
• [12]Dewachter P, Laroche D, Mouton-Faivre C, Bloch-Morot E, Cercueil JP, Metge L, Carette MF, Vergnaud MC, Clément O: Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol 2011, 77:495-501.
• [13]Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD: Prevalence of acute reactions to iopromide: post-marketing surveillance study of 74, 717 patients. Acta Radiol 2008, 49:902-911.
• [14]Lasser EC: X-ray contrast media mechanisms in the release of mast cell contents: understanding these leads to a treatment for allergies. J Allergy (Cairo) 2011, 2011:276258.
• [15]Lasser EC: Nonionic iodinated contrast media reactions. AJR Am J Roentgenol 2009, 192:W80.
• [16]Lieberman PL, Seigle RL: Reactions to radiocontrast material. Anaphylactoid events in radiology. Clin Rev Allergy Immunol 1999, 17:469-496.
• [17]Lorusso V, Taroni P, Alvino S, Spinazzi A: Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stagerenal disease requiring hemodialysis. Invest Radiol 2001, 36:309-316.